A week before Science|Business brings together experts from Europe to discuss personalised medicine here, we look at what’s happening in the US.

French innovation-focused mutual funds can make tax-efficient equity investments in ExonHit Therapeutics for renewable 3-year periods.

France’s small biopharmaceutical and life science companies have been weakened by the financial crisis and had to face a drastic drop in investment in 2009.

Knowledge management specialist Aureus Pharma is to take part in the BioIntelligence R&D programme, part-funded by the French government.